ARTICLE | Company News
FDA approves Alkermes' Aristada
October 6, 2015 1:29 AM UTC
Alkermes plc (NASDAQ:ALKS) gained $3.73 to $63.50 in after-hours trading after it said FDA approved Aristada aripiprazole lauroxil to treat schizophrenia. The company said it is preparing to launch Aristada "immediately." Alkermes spokesperson Kathryn Morris declined to disclose a price for the injectable, extended-release formulation of aripiprazole using LinkeRx technology.
Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and H. Lundbeck A/S (CSE:LUN) market Abilify Maintena, a once-monthly intramuscular depot formulation of aripiprazole (see BioCentury Extra, July 13). ...